Comparative Pharmacology
Head-to-head clinical analysis: DIONOSIL OILY versus HYPAQUE CYSTO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIONOSIL OILY versus HYPAQUE CYSTO.
DIONOSIL OILY vs HYPAQUE-CYSTO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DIONOSIL OILY is a radiographic contrast agent containing propyliodone, which is an iodine-containing compound that absorbs X-rays, thereby enhancing the visualization of body structures during imaging procedures.
HYPAQUE-CYSTO (diatrizoate meglumine) is a radiopaque contrast agent that absorbs x-rays, providing contrast in radiographic imaging. It acts as an iodinated contrast medium.
Adults: 10 mL intraurethral instillation as a sterile oily suspension (50% w/v) once daily for 3-5 days.
Intravesical instillation: 100-300 mL of 30% solution for retrograde cystourethrography; single administration.
None Documented
None Documented
Terminal elimination half-life of the iodine moiety is approximately 60 days due to slow release from fatty tissues. This long half-life reflects the persistence of the oily vehicle and slow deiodination, necessitating monitoring for cumulative iodine effects.
Terminal elimination half-life: 1.5–2.5 hours (normal renal function). Prolonged in renal impairment.
Primarily renal excretion of the water-soluble metabolite (propiodone) after hepatic deiodination; approximately 60-80% of the administered iodine is excreted in urine within 48 hours. Fecal excretion is negligible (<5%).
Renal excretion via glomerular filtration: >95% unchanged within 24 hours. Fecal excretion: <5%.
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent